<DOC>
	<DOCNO>NCT02669329</DOCNO>
	<brief_summary>Evaluate safety efficacy ZELTIQ CoolSculpting System use specialized surface applicator non-invasive subcutaneous fat reduction upper arm .</brief_summary>
	<brief_title>CoolSculpting Upper Arm Study</brief_title>
	<detailed_description />
	<mesh_term>Lipid Metabolism Disorders</mesh_term>
	<criteria>Inclusion Criteria Male female subject &gt; 22 year age &lt; 65 year age . Subject clearly visible fat sufficient treatment upper arm , investigator 's opinion , may benefit treatment . No weight change exceed 5 % precede month . Subject agree maintain his/her weight ( i.e. , within 5 % total body weight ) make major change diet exercise routine course study . Subject read sign study write informed consent form . Exclusion Criteria History fat reduction procedure ( e.g. , liposuction , surgery , lipolytic agent , etc . ) , implant adjacent area intend treatment . History prior surgery arm . Known history cryoglobulinemia , cold urticaria , cold agglutinin disease , paroxysmal cold hemoglobinuria . Known history Raynaud 's disease , know condition response cold exposure limit blood flow skin . History bleed disorder take medication investigator 's opinion may increase subject 's risk bruising . History carpal tunnel syndrome , compartment syndrome deep vein thrombosis upper extremity . Currently take take diet pill weight control supplement within past month . Any dermatological condition , scar , infection , location treatment area may interfere treatment evaluation . Active implanted device pacemaker , defibrillator , drug delivery system . Pregnant intend become pregnant next 5 month . Lactating lactate past 6 month . Unable unwilling comply study requirement . Currently enrol clinical study unapproved investigational drug device . Any condition laboratory value would , professional opinion investigator , potentially affect subject 's response integrity data would pose unacceptable risk subject .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>